IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in IN8BIO, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- −1 vs. Q3 2022
- Shares held
- 1.21M
- +7.30K (+0.6%) vs. Q3 2022
- Total value
- $2.79M
- +$368.1K (+15.2%) vs. Q3 2022
- New holders
- 4
- 5 more added
- Sold out
- 5
- 4 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INAB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 21 | $5.35M |
| Q1 2026 | 19 | $5.55M |
| Q4 2025 | 22 | $7.45M |
| Q3 2025 | 19 | $2.13M |
| Q2 2025 | 12 | $1.83M |
| Q1 2025 | 28 | $3.60M |
| Q4 2024 | 26 | $7.72M |
| Q3 2024 | 26 | $2.06M |
| Q2 2024 | 26 | $6.77M |
| Q1 2024 | 32 | $10.2M |
| Q4 2023 | 30 | $11.4M |
| Q3 2023 | 21 | $2.58M |
| Q2 2023 | 22 | $3.59M |
| Q1 2023 | 17 | $1.78M |
| Q4 2022 | 16 | $2.79M |
| Q3 2022 | 17 | $2.42M |
| Q2 2022 | 15 | $5.50M |
| Q1 2022 | 14 | $7.02M |
| Q4 2021 | 14 | $7.80M |
| Q3 2021 | 13 | $12.2M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding IN8BIO, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Voss Capital, LLC | 338,019 | $780.8K | 0.15% | −37,551−10.0% | Reduced |
| Stonegate Investment Group, LLC | 232,310 | $536.6K | 0.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 168,656 | $389.6K | 0.00% | −872−0.5% | Reduced |
| Sigma Planning Corp | 99,150 | $229.0K | 0.01% | +400+0.4% | Added |
| Rock Creek Group, LP | 81,568 | $188.4K | 0.02% | +81,568 | New |
| Bridgeway Capital Management, LLC | 74,000 | $170.9K | 0.00% | 00.0% | Unchanged |
| Ensign Peak Advisors, Inc | 70,028 | $161.8K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 58,665 | $135.0K | 0.00% | +6,318+12.1% | Added |
| BlackRock Inc. | 31,531 | $72.8K | 0.00% | +8,177+35.0% | Added |
| Northern Trust Corp | 13,253 | $30.6K | 0.00% | +13,253 | New |
| Dimensional Fund Advisors LP | 11,153 | $26.0K | 0.00% | +11,153 | New |
| Wells Fargo & Company | 10,124 | $23.4K | 0.00% | +10,065+17,059.3% | Added |
| HighTower Advisors, LLC | 10,000 | $23.0K | 0.00% | −4,164−29.4% | Reduced |
| Tower Research Capital LLC (TRC) | 6,672 | $15.0K | 0.00% | +4,851+266.4% | Added |
| UBS Group AG | 3,460 | $7.99K | 0.00% | −5,264−60.3% | Reduced |
| Bank of America Corp | 20 | $46 | 0.00% | +20 | New |
| Precept Management LLC | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| United Asset Strategies, Inc. | 0 | $0 | 0.00% | −14,000−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −1,513−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −140−100.0% | Sold out |